Cargando…
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
Osteosarcoma (OS) is a bone cancer mostly occurring in pediatric population. Current treatment regime of surgery and intensive chemotherapy could cure about 60%–75% patients with primary osteosarcoma, however only 15% to 30% can be cured when pulmonary metastasis or relapse has taken place. Hence, n...
Autores principales: | Shaikh, Atik Badshah, Li, Fangfei, Li, Min, He, Bing, He, Xiaojuan, Chen, Guofen, Guo, Baosheng, Li, Defang, Jiang, Feng, Dang, Lei, Zheng, Shaowei, Liang, Chao, Liu, Jin, Lu, Cheng, Liu, Biao, Lu, Jun, Wang, Luyao, Lu, Aiping, Zhang, Ge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848962/ https://www.ncbi.nlm.nih.gov/pubmed/27058531 http://dx.doi.org/10.3390/ijms17040506 |
Ejemplares similares
-
Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders
por: Dang, Lei, et al.
Publicado: (2016) -
Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems
por: Jiang, Feng, et al.
Publicado: (2015) -
Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer
por: Liu, Jin, et al.
Publicado: (2017) -
Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis
por: He, Xiaojuan, et al.
Publicado: (2019) -
Corrigendum to ‘Osteoblastic PLEKHO1 contributes to joint inflammation in rheumatoid arthritis’ [EBioMedicine 41 (2019) 538–555]
por: He, Xiaojuan, et al.
Publicado: (2020)